Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Gene Therapy00:59

Gene Therapy

28.0K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
28.0K
Gene Therapy00:59

Gene Therapy

4.8K
4.8K
Coagulation01:09

Coagulation

11.8K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.8K
Coagulation01:06

Coagulation

1.6K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Generational advancement of factor VIIIa mimetics.

Blood·2026
Same author

Factor VIII <i>in vitro</i> bioequivalence of denecimig (Mim8) hemostatic effect by thrombin generation assays.

Research and practice in thrombosis and haemostasis·2026
Same author

Translational insights from nonclinical studies of AAV gene therapies for hemophilia: mechanisms underpinning variability and durability of gene expression.

Therapeutic advances in hematology·2026
Same author

Molecular genetic testing in von Willebrand disease: past, present, and beyond.

Haematologica·2026
Same author

Large deletions in the <i>F8</i> gene predict immune tolerance induction failure in people with severe hemophilia A.

Research and practice in thrombosis and haemostasis·2025
Same author

Von Willebrand factor and von Willebrand disease in ageing: mechanisms, evolving phenotypes, and clinical implications.

The Lancet. Haematology·2025
Same journal

SBK2 Links Cardiac Stress Signaling to Mitochondrial Proteostasis.

Circulation research·2026
Same journal

Myeloid Piezo1 as a Brake on Efferocytosis and Cardiac Repair in the Infarcted Heart.

Circulation research·2026
Same journal

Targeting Late Na<sup>+</sup> Current: Too Late or Better Late Than Never?

Circulation research·2026
Same journal

HFpEF-Any: Human Single-Nuclear Transcriptomics Challenging the Translational Validity of Current HFpEF Models.

Circulation research·2026
Same journal

Myovascular Niche: The Role of Endothelial Cells in Skeletal Muscle Health and Disease.

Circulation research·2026
Same journal

Meet the First Authors.

Circulation research·2026
See all related articles

Related Experiment Video

Updated: Mar 22, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.4K

Gene Therapy for Coagulation Disorders.

Laura L Swystun1, David Lillicrap2

  • 1From the Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.

Circulation Research
|April 30, 2016
PubMed
Summary
This summary is machine-generated.

Gene therapy offers a promising future for treating inherited bleeding disorders like hemophilia B. Adeno-associated virus vectors have shown success in delivering factor IX, but challenges like immune responses remain.

Keywords:
bleedingcoagulationfactor IXfactor VIIIgene therapygene transferhemophilia

More Related Videos

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

65

Related Experiment Videos

Last Updated: Mar 22, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

15.4K
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
06:59

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well

Published on: February 27, 2026

65

Area of Science:

  • Coagulation genetics
  • Molecular diagnostics
  • Gene therapy for hemostasis

Background:

  • The 1980s genetic revolution elucidated human coagulation factors, enabling molecular diagnostics and recombinant therapies for bleeding disorders.
  • Gene transfer aims to provide continuous access to essential hemostatic proteins, addressing inherited coagulation factor deficiencies.

Purpose of the Study:

  • To review the progress and challenges of gene therapy for inherited coagulation disorders.
  • To highlight the potential of gene transfer for treating hemostasis defects.

Main Methods:

  • Review of adeno-associated virus (AAV)-based gene transfer strategies for factor IX in hemophilia B.
  • Analysis of clinical trial data from phase 1/2 studies.

Main Results:

  • Prolonged expression of therapeutic levels of factor IX achieved in hemophilia B patients using AAV vectors.
  • Demonstrated clinical successes in early-phase gene therapy trials for coagulation disorders.

Conclusions:

  • Gene therapy, particularly AAV-based approaches, shows significant promise for treating inherited bleeding disorders.
  • Overcoming immunologic responses and enhancing vector production are crucial for widespread clinical application.
  • Advancements in genome editing and nucleic acid-based therapies will shape the future of hemostasis treatment.